SIOUX FALLS, S.D., June 10, 2021–SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company developing a novel immunotherapy platform to produce specifically targeted, high potency, fully-human polyclonal antibodies, today announced the appointment of Carlos Carrillo, PhD, as senior vice president, regulatory affairs. Dr. Carrillo brings over 25 years of experience managing regulatory strategy in the biopharmaceutical industry, along with CMC and process development expertise.
“We are pleased to welcome Carlos to SAB Biotherapeutics at such an important time for the company,” said Eddie J. Sullivan, PhD, co-founder, president and CEO of SAB Biotherapeutics. “Carlos has an accomplished track record of overseeing all aspects of the biopharmaceutical regulatory process, including formulating strategy, managing submissions, and working closely with the FDA. His experience will be valuable as we expand and progress our proprietary technology platform and multiple clinical stage programs.”
Dr. Carrillo has held global leadership roles in regulatory affairs and project management at a number of dynamic biopharmaceutical and healthcare companies. Prior to joining SAB, he was director, regulatory affairs at Sagent Pharmaceuticals, where he was responsible for communicating with the FDA and providing guidance to the discovery, process development, quality and manufacturing teams. Earlier, Dr. Carrillo worked as director, regulatory affairs/product portfolio at Johnson Matthey Pharma Ventures, where he managed regulatory assessments of CMC changes and executed regulatory planning and implementation. Before that, he was director, regulatory affairs/project management at Wockhardt and global project management at Fresenius Kabi. Dr. Carrillo has additionally held roles at Hospira, Metrics, and Abbott Laboratories. He received his PhD in Regulatory Law and Policy of Drug Products, Medical Devices, Biologics and his MS in Drug Product Development, Patent and Intellectual Law, both from Northeastern University.
“SAB has developed an innovative technology platform that leverages the natural human immune response to produce potent and specific polyclonal antibodies, offering a differentiated therapeutic option with many potential applications in immunotherapy-related conditions,” said Dr. Carrillo. “I am excited to join SAB at such an important time in the company’s development as it advances and expands multiple clinical programs, and I look forward to contributing to the rapid progress in addressing serious diseases with major unmet needs.”
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc. (SAB) is a clinical-stage biopharmaceutical company advancing a new class of immunotherapies based on its human polyclonal antibodies. Utilizing some of the world’s most advanced genetic engineering and antibody science, SAB has developed transgenic bovine herds that produce fully human antibodies targeted at fighting specific diseases, including infectious diseases such as COVID-19 and influenza; immune-related disorders including type 1 diabetes, organ transplantation and other autoimmune diseases; as well as complex immune-mediated diseases such as cancer. SAB’s flexible and scalable DiversitAb™ platform is applicable to a wide range of serious human diseases. It rapidly produces natural, specifically targeted, high-potency, human polyclonal immunotherapies at commercial scale. Development and validation of the platform have benefitted from major support from key US government emerging disease and rapid response programs. The Company is currently advancing multiple clinical programs in a number of indications in addition to collaborations with global pharmaceutical and other partners. For more information visit: www.sab.bio and follow @SABBantibody on Twitter.
Contacts:
Melissa Ullerich
+1 605-695-8350
mullerich@sab.bio
Stern Investor Relations
Courtney Turiano
+1 212-362-1200
courtney.turiano@sternir.com
